Articles From: Celladon Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares to Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September


SAN DIEGO, Aug.
Sign-up for Celladon Announces Commencement of Public Offering of Common Stock investment picks
SAN DIEGO, Aug.
Sign-up for Celladon Announces Pricing of Public Offering of Common Stock investment picks
SAN DIEGO, July 21, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN) , a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation today announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
Sign-up for Celladon Corporation Announces In-License of Stem Cell Factor Development Program investment picks
SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN) , a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has launched two new clinical development initiatives for MYDICAR®, its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies.
Sign-up for Celladon Corporation Announces New Clinical Development Initiatives for MYDICAR(R) investment picks
SAN DIEGO, July 30, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN) , a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it will report its results for the second quarter ended June 30, 2014 on Thursday, August 7, 2014.
Sign-up for Celladon to Report Second Quarter 2014 Results on August 7, 2014 investment picks
NETANYA, Israel , July 2, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces 4G Frequencies Tender Published investment picks
NETANYA, Israel , July 6, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Extension Of D&O Indemnification And Exemption investment picks
NETANYA, Israel , June 23, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Filing of Shelf Prospectus in Israel in Preparation for Debt Offering in Israel investment picks
NETANYA, Israel , July 6, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Filing Of Supplemental Shelf Offering Report In Israel investment picks
NETANYA, Israel , July 31, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Hearing Regarding 2G and 3G Coverage and Quality Requirements investment picks
NETANYA, Israel , August 19, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom israel Announces Hearing Regarding Call Center Services investment picks
NETANYA, Israel , August 14, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Hearing Regarding Roaming Services Abroad investment picks
NETANYA, Israel , July 31, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces LTE Network Launch investment picks
NETANYA, Israel , July 30, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Partial Dismissal Of Purported Class Actions investment picks
NETANYA, Israel , July 8, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Results of its Debenture Offering in Israel investment picks
NETANYA, Israel , August 17, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Announces Sale of Appx. 0.93% of its Issued Share Capital by Option Holders investment picks
2014/8/11
Net income for the second quarter of 2014 totaled NIS 79 million, a 17.9% increase compared with the second quarter of 2013 EBITDA[1] for the second quarter of 2014 totaled NIS 314 million[2], a 7.4% decrease compared with the second quarter of 2013; excluding one-time effects EBITDA totaled NIS 331 million, a 2.4% decrease compared with the second quarter of 2013 Free cash flow[1] for the second quarter of 2014 totaled NIS 361 million, a 4.6% increase compared with the second quarter of 2013 The Company completed a retirement plan in which approximately 380 employees have retired with a one-time cost of approximately NIS 39 million.
Sign-up for Cellcom Israel Announces Second Quarter 2014 Results investment picks
Conference Call Scheduled for August 11, 2014 at 9:00 ET NETANYA, Israel , July 24, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Schedules Second Quarter 2014 Results Release for August 11, 2014 investment picks
Amdocs software to replace disparate customer relationship management (CRM) systems for consolidated support across all lines of business; existing managed services engagement extended to cover CRM operations ST.
Sign-up for Cellcom Israel Selects Amdocs Software and Services to Modernize and Consolidate Customer Relationship Management Operations investment picks
HAMPTON, N.J., Sept.
Sign-up for Celldex Announces Upcoming Presentation at the Morgan Stanley Healthcare Conference investment picks
HAMPTON, N.J., Aug.
Sign-up for Celldex Reports Second Quarter 2014 Results investment picks
HAMPTON, N.J., July 30, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced three promotions in the Company's clinical and research departments: "We continue to build an exceptional team of senior leaders at Celldex who are committed to advancing our pipeline and improving the lives of patients facing cancer," said Anthony Marucci, President and Chief Executive Officer of Celldex.
Sign-up for Celldex Therapeutics Announces Senior Leadership Promotions investment picks
HAMPTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2014 financial results on Wednesday, August 6, 2014 after the U.S. financial markets close.
Sign-up for Celldex to Report Second Quarter 2014 Financial Results and Host Corporate 2014 Objectives Update Call investment picks
Rodman & Renshaw 16 th Annual Global Investment Conference on September 9, 2014 Aegis Capital 2014 Healthcare and Technology Conference on September 11, 2014 Webcasts Available Through Cellectar Corporate Website MADISON, Wis., Sept.
Sign-up for Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Celladon Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares to Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices